Antony Loebel

Chief Medical Officer and President of Clinical Development, Seaport Therapeutics

Search every verified Antony Loebel interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Antony Loebel, Chief Medical Officer and President of Clinical Development at Seaport Therapeutics, discussed findings from the first placebo-controlled trial for patients with major depressive disorder with mixed features, presented in 2015 while he was at Sunovion Pharmaceuticals. He noted that the DSM-5, published in 2013, introduced a mixed features specifier, enabling better identification of patients who have major depressive disorder with a limited number of manic symptoms, falling between major depression and bipolar disorder. Loebel stated that the trial evaluated the atypical antipsychotic Latuda and showed significant effectiveness in this patient population, with what he described as good tolerability, including limited effects on weight, lipids, glucose, and prolactin, and a lower overall discontinuation rate compared to placebo. He characterized the study as the first evidence base to guide treatment for this condition.